These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 12839083)

  • 1. The hematologic system as a marker of organ dysfunction in sepsis.
    Aird WC
    Mayo Clin Proc; 2003 Jul; 78(7):869-81. PubMed ID: 12839083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hematologic changes in sepsis and their therapeutic implications.
    Goyette RE; Key NS; Ely EW
    Semin Respir Crit Care Med; 2004 Dec; 25(6):645-59. PubMed ID: 16088507
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advances in the understanding of clinical manifestations and therapy of severe sepsis: an update for critical care nurses.
    Ely EW; Kleinpell RM; Goyette RE
    Am J Crit Care; 2003 Mar; 12(2):120-33; quiz 134-5. PubMed ID: 12625170
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospectively validated predictions of shock and organ failure in individual septic surgical patients: the Systemic Mediator Associated Response Test.
    Slotman GJ
    Crit Care; 2000; 4(5):319-26. PubMed ID: 11056759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug-associated disease: hematologic dysfunction.
    Vandendries ER; Drews RE
    Crit Care Clin; 2006 Apr; 22(2):347-55, viii. PubMed ID: 16678004
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anemia in the critically ill.
    Shander A
    Crit Care Clin; 2004 Apr; 20(2):159-78. PubMed ID: 15135458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Severe protein C deficiency is associated with organ dysfunction in patients with severe sepsis.
    Shaw AD; Vail GM; Haney DJ; Xie J; Williams MD
    J Crit Care; 2011 Dec; 26(6):539-45. PubMed ID: 21737232
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of recombinant human erythropoietin in critically ill patients admitted to a long-term acute care facility: a randomized, double-blind, placebo-controlled trial.
    Silver M; Corwin MJ; Bazan A; Gettinger A; Enny C; Corwin HL
    Crit Care Med; 2006 Sep; 34(9):2310-6. PubMed ID: 16878035
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hematologic failure.
    Levi M; Schultz M
    Semin Respir Crit Care Med; 2011 Oct; 32(5):651-9. PubMed ID: 21989700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hematologic Dysfunction Criteria in Critically Ill Children: The PODIUM Consensus Conference.
    Muszynski JA; Cholette JM; Steiner ME; Tucci M; Doctor A; Parker RI;
    Pediatrics; 2022 Jan; 149(1 Suppl 1):S74-S78. PubMed ID: 34970675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bench to bedside: A role for erythropoietin in sepsis.
    Walden AP; Young JD; Sharples E
    Crit Care; 2010; 14(4):227. PubMed ID: 20727227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Committee for Standards in Haematology.
    Levi M; Toh CH; Thachil J; Watson HG
    Br J Haematol; 2009 Apr; 145(1):24-33. PubMed ID: 19222477
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Red blood cell transfusion thresholds in pediatric patients with sepsis.
    Karam O; Tucci M; Ducruet T; Hume HA; Lacroix J; Gauvin F; ;
    Pediatr Crit Care Med; 2011 Sep; 12(5):512-8. PubMed ID: 21057356
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The current management of septic shock.
    Russel JA
    Minerva Med; 2008 Oct; 99(5):431-58. PubMed ID: 18971911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adding growth factors or interleukin-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone.
    Musto P; Sanpaolo G; D'Arena G; Scalzulli PR; Matera R; Falcone A; Bodenizza C; Perla G; Carotenuto M
    Haematologica; 2001 Jan; 86(1):44-51. PubMed ID: 11146570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Physician Education: Myelodysplastic Syndrome.
    Yoshida Y
    Oncologist; 1996; 1(4):284-287. PubMed ID: 10388004
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inflammation and coagulation: implications for the septic patient.
    Dellinger RP
    Clin Infect Dis; 2003 May; 36(10):1259-65. PubMed ID: 12746771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activated protein C: controversy and hope in the treatment of sepsis.
    Baillie JK
    Curr Opin Investig Drugs; 2007 Nov; 8(11):933-8. PubMed ID: 17979027
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant human granulocyte-macrophage colony-stimulating factor plus erythropoietin for the treatment of cytopenias in patients with myelodysplastic syndromes.
    Stasi R; Pagano A; Terzoli E; Amadori S
    Br J Haematol; 1999 Apr; 105(1):141-8. PubMed ID: 10233377
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The coagulopathy of sepsis: pathophysiology and management.
    Satran R; Almog Y
    Isr Med Assoc J; 2003 Jul; 5(7):516-20. PubMed ID: 12901250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.